Coffee Sipping Big Board Stocks

[timhyma]

6:06 am EXACT Sciences beats by $0.06, misses on revs; guides FY16 revs in-line (EXAS) :

Reports Q4 (Dec) loss of $0.41 per share, $0.06 better than the Capital IQ Consensus of ($0.47); revenues rose 861.3% year/year to $14.42 mln vs the $14.76 mln Capital IQ Consensus.
•Co issues in-line guidance for FY16, sees FY16 revs of $90-100 mln vs. $94.06 mln Capital IQ Consensus Estimate; continues to anticipate completing more than 240,000 Cologuard tests during 2016
•Exact Sciences ended 2015 with cash, cash equivalents and marketable securities of $306.9 million, compared to $282.8 million at December 31, 2014.
•The cumulative number of physicians ordering Cologuard expanded steadily in 2015. During the fourth quarter of 2015 this total grew 27 percent from the third quarter to nearly 27,000 physicians. On average, approximately 500 new physicians ordered Cologuard each week and 75 percent of physicians re-ordered the FDA-approved, non-invasive colon cancer screening test. The patient compliance rate with Cologuard at the end of 2015 was 71 percent.